Pfizer Finally Gets a Hit!

Pfizer (NYSE: PFE  ) has had a rough start to 2009. Investors have been less than enthusiastic about its acquisition of Wyeth (NYSE: WYE  ) and concurrent dividend cut. But yesterday, the drug giant finally had some good news to share with investors.

The company ended a clinical trial early because its cancer drug Sutent was able to stop the progression of a rare form of pancreatic cancer -- the same type that Steve Jobs of Apple (Nasdaq: AAPL  ) was reported to have -- better than placebo. When it becomes clear that a drug works, independent data monitoring boards stop trials early so that patients getting placebo can be transferred to the drug. That's very good news for patients and for sales of Sutent.

Sutent is currently approved to treat kidney cancer and a digestive-tract cancer. The drug managed sales of $847 million last year, up 46% year over year. But most of that increase came from outside the United States. Sales were up just 7% in the U.S., as the drug has a lot of competition from Onyx Pharmaceuticals' (Nasdaq: ONXX  ) Nexavar and Wyeth's Torisel. The additional patients should give sales a boost, albeit a minor one given the relatively small number of patients with the pancreatic cancer.

Beyond that, the results are encouraging because they suggest that Sutent might be useful in treating other cancers -- breast, lung, colon, prostate, and liver. It's not a guarantee for success -- Nexavar didn't work for skin or lung cancer, for instance -- but it certainly should give Pfizer shareholders hope that Sutent might be able to approach the sales levels seen by Genentech's (NYSE: DNA  ) Avastin, which topped $2.6 billion last year.

Now Pfizer just needs a few more good results like this, and the ability to integrate a $68 billion purchase better than it has in the past, and it can get back to growing again -- post-Lipitor exclusivity, of course.

More Foolishness:

Pfizer is a Motley Fool Inside Value recommendation. If you're interested in picking through the wreckage for possible turnaround candidates, you should have the Inside Value team on your side. Check it out for free with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a former Income Investor selection. Apple is a choice at Stock Advisor. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (16)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 851302, ~/Articles/ArticleHandler.aspx, 11/28/2014 12:57:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement